

February 22, 1972

Mr. L. R. Hines, Ph.D.
Director of Biological Research
Hoffmann-La Roche, Inc.
Nutley, New Jersey 07110

Dear Len:

I have read the data sheets on Lorfan and R0 4-6711 with interest, focussing on their possible use in opiate dependence.

The data on Ro 4-6711 shows this to be similar to cyclazocine in structure, with similar side-effects on low oral dosage (0.5 mg) - sleepy, uncomfortable thoughts, "drunk", but with vomiting also. These effects reflect a high degree of agonistic effects, considerably reducing our interest.

The data on Lorfan is more promising. It is a well defined antagonist, and a program designed to extend its duration of action may be useful. It may be important, however, to clarify the comment in the package insert, regarding enhanced respiratory depression with repeated doses. If verified, this will be a deterrent to further development.

Thanks for the opportunity to review these data.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:ig